ANVS
Annovis Bio, Inc. (NYSE)
Healthcare — Biotechnology
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Price History
Fundamentals
| Market Cap | $79.13M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.60 |
| EPS (TTM) | $-1.71 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -301.13% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $12.50 |
| Analysts | 2 |
| Indexes | NYSE |
Technical Indicators
| RSI (14) | 57.1 |
| Beta | 1.19 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.50 |
| 52-Week Low | $1.54 |
| 50-Day Avg | $1.95 |
| 200-Day Avg | $2.55 |
| Avg Volume | $1.22M |
| Volume | 633.7K |
Performance Analysis
BULLISHANVS shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report